Reagent Kit HemeScreen® HRM Screening RUNX1 For use with HRM-enabled RT-PCR Machine / Cytopenia Panel 100 Tests
Precipio’s HemeScreen® offerings are Research Use Only (RUO) assays that screen for clinically actionable somatic mutations in targets of interest related to myeloproliferative disorders and haematological cancers
Product Specifications
Description
The reagents are designed to be used in a clinical diagnostic laboratory by suitably trained personnel testing DNA extracted from whole blood or bone marrow using a PCR-based method and High Resolution Melt (HRM) Analysis
RUNX1 (runt-related transcription factor 1) mutation is commonly seen in chemotherapy-related MDS, but is also seen in MDS, AML, as well as AML after MDS
RUNX1 mutation is also associated with abnormal cytogenetics, including monosomy 7, trisomy 21 and trisomy 13. RUNX1 and monosomy 7 can lead to rapid progression of AML when the patient is being treated for MDS; CEBPA and NPM1 are not commonly associated with mutated RUNX1
RUNX1 mutation has a poor prognosis regardless of cytogenetic abnormalities and should be considered in the diagnosis of AML
Machine required HRM-enabled RT-PCR (example/ ThermoFisher Quantstudio 3 or higher)